Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Intrinsic Value
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. [ Read More ]
The intrinsic value of one
REGN
stock under the Base Case scenario is
572.21
USD.
Compared to the current market price of 909.87 USD,
Regeneron Pharmaceuticals Inc
is
Overvalued by 37%.
Regeneron Pharmaceuticals Inc's market capitalization is 99.5B USD.
REGN stock price is 909.87 USD.
REGN stock (572.21 USD) is 37% less than its price (909.87 USD).
REGN stock (542.77 USD) is 40% less than its price (909.87 USD). Open DCF Valuation
REGN stock (601.66 USD) is 34% less than its price (909.87 USD). Open Relative Valuation
REGN has upside potential of 18% compared to the average analyst price target.
Open Wall St Estimates
REGN's Revenue has grown by 8% over the past 12 months.
REGN's ROIC (Return on Invested Capital) has increased in the last 3 years from 29% to 32%.
REGN's ROE (Return on Equity) for the past 12 months is positive and is equal to 16%.
REGN's Revenue is forecast to grow at a rate of 7% per year over the next 3 years.
REGN's Revenue has been growing by 16% per year for the last 3 years.
REGN's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 32%.
REGN's ROE (Return on Equity) has significantly decreased in the last 3 years from 33% to 16%.
REGN has positive Operating Income for the last twelve months.
REGN has positive Net Income for the last twelve months.
REGN has very high three-year average ROIC (Return on Invested Capital): 32%. The company is very efficient at using invested capital to generate operating income.
REGN has positive Gross Profit for the last twelve months.
REGN has very high three-year average ROE (Return on Equity): 33%. The company is very efficient at transforming stockholders' equity into net income.
REGN has positive Free Cash Flow for the last twelve months.
REGN's D/E (Debt to Equity) is very low and is equal to 0.1.
REGN's short-term assets (19B USD) exceed its short-term liabilties (3B USD).
REGN's long-term assets (33B USD) exceed its long-term liabilties (7B USD).
REGN has negative Net Debt. This means that the company has more cash and short-term investments (24B USD) than debt (3B USD).
REGN's Altman Z-Score is very high and is equal to 9.78.
REGN earns more than enough operating income (4B USD) to safely cover interest payments on its debt (73m USD).
Valuation Backtest
Regeneron Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
REGN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Regeneron Pharmaceuticals Inc
Balance Sheet Decomposition
Regeneron Pharmaceuticals Inc
| Current Assets | 19.5B |
| Cash & Short-Term Investments | 24.4B |
| Receivables | 5.7B |
| Other Current Assets | -10.5B |
| Non-Current Assets | 13.6B |
| Long-Term Investments | 5.5B |
| PP&E | 4.1B |
| Intangibles | 1B |
| Other Non-Current Assets | 2.9B |
| Current Liabilities | 3.4B |
| Accounts Payable | 4.4B |
| Accrued Liabilities | 2.4B |
| Other Current Liabilities | -3.4B |
| Non-Current Liabilities | 3.7B |
| Long-Term Debt | 2.7B |
| Other Non-Current Liabilities | 980.8m |
Earnings Waterfall
Regeneron Pharmaceuticals Inc
|
Revenue
|
13.1B
USD
|
|
Cost of Revenue
|
-1.8B
USD
|
|
Gross Profit
|
11.3B
USD
|
|
Operating Expenses
|
-7.1B
USD
|
|
Operating Income
|
4.2B
USD
|
|
Other Expenses
|
-279.6m
USD
|
|
Net Income
|
4B
USD
|
Free Cash Flow Analysis
Regeneron Pharmaceuticals Inc
REGN Profitability Score
Profitability Due Diligence
Regeneron Pharmaceuticals Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
Score
Regeneron Pharmaceuticals Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
REGN Solvency Score
Solvency Due Diligence
Regeneron Pharmaceuticals Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Regeneron Pharmaceuticals Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
REGN Price Targets Summary
Regeneron Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
REGN
is 1 069.29 USD
with a low forecast of 727.2 USD and a high forecast of 1 248.45 USD.
Ownership
REGN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
REGN Price
Regeneron Pharmaceuticals Inc
| Average Annual Return | 20.94% |
| Standard Deviation of Annual Returns | 10.23% |
| Max Drawdown | -22% |
| Market Capitalization | 99.5B USD |
| Shares Outstanding | 109 760 000 |
| Percentage of Shares Shorted | 1.54% |
REGN News
Last Important Events
Regeneron Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Regeneron Pharmaceuticals Inc
Company Profile
Regeneron Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 10,368 full-time employees. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. The firm's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. Its product candidates in clinical development include REGN4018, REGN5668, and Fasinumab, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
REGN
stock under the Base Case scenario is
572.21
USD.
Compared to the current market price of 909.87 USD,
Regeneron Pharmaceuticals Inc
is
Overvalued by 37%.
You don't have any saved screeners yet
